CA125与TSGF联合检测在卵巢癌中的临床应用

为探讨ＣＡ１２５ 、ＴＳＧＦ 联合测定在卵巢癌诊断、疗效观察中的价值，分别测定正常妇女、卵巢良性肿瘤患者和７５ 例卵巢癌患者术前和术后或治疗后的血清ＣＡ１２５ 、ＴＳＧＦ 水平。结果：卵巢癌患者ＣＡ１２５ 、ＴＳＣＦ 阳性率分别为８８ ．０ ％ 、９０ ．７ ％ ，联合测定阳性率为９６ ．０ ％ ；随访５１ 例术后患者中，有１６ 例患者血清ＣＡ１２５ 和（ 或） ＴＳＧＦ 升高，在血清学变化的３～１２ 个月内被临床证实转移或复发。认为联合测定ＣＡ１２５ 、ＴＳＧＦ 不仅可提高卵巢癌的阳性诊断率，还可进行疗效观察及术后监测，且能达到早期诊断的目的。

Clinical application ofcombined detection of serumCA125 and TSGF in ovarian cancer

In order to discuss the value of combined detection of CA125 and tumor specific growth factor (TSGF) in the diagnosis of ovarian cancer and the therapeutic effects, the serum level of CA125 and TSGF was detected, respectively in healthy women, patients with benign tumor of ovary and 75 cases of ovarian cancer before and after operation or after treatment. Results showed that positive rates of CA125 and TSGF in cases of ovarian cancer were 88% and 90.7%, respectively. The positive rate with combined detection was 96.0%. Serum CA125 and TSGF increased in 16 out of 51 follow-up cases. They were clinically confirmed to metastasize or recur within 3～12 months with serological changes. It could be concluded that the combined detection of CA125 and TSGF not only improves the diagnostic positive rate of ovarian cancer but also helps to observe therapeutic effect and postoperative monitoring and to reach the goal of early diagnosis.